DURECT announces FDA agreed to file the full response to POSIMIR® CRL as a resubmission
DURECT announced the FDA has acknowledged the submission of DURECT's full response to the Complete Response Letter related to POSIMIR® (bupivacaine extended-release solution) is considered by the FDA to be a complete class 2 response to the CRL. The user fee goal date is Dec. 27, 2019. July 17, 2019